172 Results for "

Cdk6

" in MedChemExpress (MCE) Product Catalog:
Products (172)

172 Results for "Cdk6" in MCE Product Catalog:

Cat. No.: HY-142696
CAS No.: 2677026-14-9
Target:  

CDK Pim Apoptosis

Research Areas:  

Cancer

CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .
loading...
    loading...
Cat. No.: HY-168620
CAS No.: 2743517-28-2
Target:  

CDK

Research Areas:  

Cancer

CDK6-IN-1 (compound 4i) is a CDK6 inhibitor. CDK6-IN-1 inhibits cell growth and induces cell cycle arrest at G1-phase .
loading...
    loading...
Cat. No.: HY-115992
CAS No.: 2688098-02-2
Target:  

CDK

Research Areas:  

Cancer

CDK4/6-IN-9 (compound 10) is a selective CDK4/6 inhibitor with an IC50 of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .
loading...
    loading...
Cat. No.: HY-I0996
CAS No.: 1023594-50-4
Target:  

CDK

Research Areas:  

Cancer

1,1-Dimethylethyl 4-(4-amino-3-pyridinyl)-1-piperazinecarboxylate is the impurity of Palbociclib (HY-50767). Palbociclib is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively .
loading...
    loading...
Cat. No.: HY-153088
CAS No.: 1169694-98-7
Target:  

CDK

Research Areas:  

Cancer

CDK4/6-IN-16 (example 195) is a potent CDK4 and CDK6 inhibitor, with an IC50 of 0.013 μM for CDK4. CDK4/6-IN-16 can be used for the research of CDK4-mediated disorders, such as cancer .
loading...
    loading...
Cat. No.: HY-128669S
Purity:  99.25%
Synonyms: LSN2839567-d6
Abemaciclib metabolite M2-d6 is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s in the range of 1-3 nM. Anti-cancer activity .
loading...
    loading...
Cat. No.: HY-108907
CAS No.: 1446715-47-4
Target:  

Casein Kinase

Research Areas:  

Cancer

SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC50s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC50s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-RS02392
Research Areas:  

Others

CDK6 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS02393
Research Areas:  

Others

Cdk6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS02394
Research Areas:  

Others

Cdk6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-175187
Target:  

CDK PROTACs

Research Areas:  

Others

LO-3-63 is a CDK4/CDK6 degrader. LO-3-63 induces proteasome-dependent degradation of CDK4/6 via CUL4 DCAF16 -dependent interaction .
loading...
    loading...
Cat. No.: HY-175013
CAS No.: 3068529-24-5
Research Areas:  

Inflammation/Immunology

CDK6/9-IN-2 is a highly active dual inhibitor of CDK6 (IC50 = 15 nM) and CDK9 (IC50 = 22 nM). CDK6/9-IN-2 is selective for CDK2, CDK8, and CDK11. CDK6/9-IN-2 inhibits the proliferation of HaCaT cells induced by IFN-γ/TNF-α and suppresses the STAT3 pathway and the expression of inflammatory factors. CDK6/9-IN-2 can alleviate psoriatic dermatitis and is useful in psoriasis research .
loading...
    loading...
Cat. No.: HY-178516
Research Areas:  

Cancer

PROTAC CDK4/6/9 degrader 1 prodrug is an orally active CDK4/CDK6/CDK9 PROTAC degrader prodrug. PROTAC CDK4/6/9 degrader 1 prodrug converts into PROTAC CDK4/6/9 degrader 1 (HY-178452). PROTAC CDK4/6/9 degrader 1 degrades CDK4, CDK6 and CDK9. PROTAC CDK4/6/9 degrader 1 prodrug is applicable to the research of triple-negative breast cancer (prodrug modification moiety: Lauric acid (HY-Y0366); PROTAC moiety: PROTAC CDK4/6/9 degrader 1 (HY-178452)) .
loading...
    loading...
Cat. No.: HY-16297R
CAS No.: 1231930-82-7
Synonyms: LY2835219 methanesulfonate (Standard)
Target:  

Reference Standards CDK

Research Areas:  

Cancer

Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .
loading...
    loading...
Cat. No.: HY-147409
CAS No.: 2075750-05-7
Target:  

CDK

Research Areas:  

Cancer

Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .
loading...
    loading...
Cat. No.: HY-184911
Research Areas:  

Cancer

CDK6 ligand-3 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) that targets CDK6. CDK6 ligand-3 can be used to synthesize the PROTAC JHK-02-108-2 (HY-184910) .
loading...
    loading...
Cat. No.: HY-180277
Target:  

PROTACs CDK Apoptosis

Research Areas:  

Cancer

PROTAC CDK6 Degrader 1 (compound 48a) is a potent and selective PROTAC CDK6 degrader with a DC50 of 0.037 μM. PROTAC CDK6 Degrader 1 exhibits selectivity over CDK4 (DC50 > 10 μM). PROTAC CDK6 Degrader 1 induces G0/G1 cell-cycle arrest and apoptosis through inhibition of CDK6 downstream signaling. PROTAC CDK6 Degrader 1 reduces tumor burden and CDK6 levels in a MOLM-14 xenograft mouse model. PROTAC CDK6 Degrader 1 can be used for CDK6-driven cancers research, such as acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-180278
Research Areas:  

Cancer

CDK6 ligand 1 is a CDK6 ligand that can be used in studies related to PROTAC synthesis, for example, acting as the target protein ligand of PROTAC CDK6 Degrader 1 (HY-180277) .
loading...
    loading...
Cat. No.: HY-180262
Target:  

PROTACs CDK

Research Areas:  

Cancer

PROTAC CDK6 Degrader 2 (compound 48b), the active form of PROTAC CDK6 Degrader 1 (HY-180277), is a potent and selective PROTAC CDK6 degrader that binds strongly to KLHDC2 (KD = 0.005 μM). PROTAC CDK6 Degrader 2 functions through a KLHDC2-dependent and ubiquitin-proteasome-mediated mechanism. PROTAC CDK6 Degrader 2 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-180279
Research Areas:  

Cancer

CDK6 ligand-Linker Conjugate 1 is a target protein ligand-linker conjugate that incorporates a ligand for CDK6 (HY-180278) and a linker, which recruits E3 ligases. CDK6 ligand-Linker Conjugate 1 can be used for synthesis of PROTAC CDK6 Degrader 1 (HY-180277) .
loading...
    loading...